Aller au contenu

Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy.

Nom du journal : J Clin Oncol

Année : 2023

Volume : 41

Page de départ : 2988-2997

Auteurs: Squifflet, P, Saad, ED, Loibl, S, van Mackelenbergh, MT, Untch, M, Rastogi, P & al,